These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 20399780)

  • 1. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.
    Thompson AJ; Muir AJ; Sulkowski MS; Ge D; Fellay J; Shianna KV; Urban T; Afdhal NH; Jacobson IM; Esteban R; Poordad F; Lawitz EJ; McCone J; Shiffman ML; Galler GW; Lee WM; Reindollar R; King JW; Kwo PY; Ghalib RH; Freilich B; Nyberg LM; Zeuzem S; Poynard T; Vock DM; Pieper KS; Patel K; Tillmann HL; Noviello S; Koury K; Pedicone LD; Brass CA; Albrecht JK; Goldstein DB; McHutchison JG
    Gastroenterology; 2010 Jul; 139(1):120-9.e18. PubMed ID: 20399780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide association of IL-28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C in a Tunisian population.
    Bizid S; Bouali R; Ouedrani A; Mrabet A; Ben Abdallah H; Ghazouani E; Abdelli N
    Tunis Med; 2016 Jan; 94(1):6-11. PubMed ID: 27525598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.
    Mangia A; Thompson AJ; Santoro R; Piazzolla V; Tillmann HL; Patel K; Shianna KV; Mottola L; Petruzzellis D; Bacca D; Carretta V; Minerva N; Goldstein DB; McHutchison JG
    Gastroenterology; 2010 Sep; 139(3):821-7, 827.e1. PubMed ID: 20621700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors that predict response of patients with hepatitis C virus infection to boceprevir.
    Poordad F; Bronowicki JP; Gordon SC; Zeuzem S; Jacobson IM; Sulkowski MS; Poynard T; Morgan TR; Molony C; Pedicone LD; Sings HL; Burroughs MH; Sniukiene V; Boparai N; Goteti VS; Brass CA; Albrecht JK; Bacon BR;
    Gastroenterology; 2012 Sep; 143(3):608-618.e5. PubMed ID: 22626609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients.
    Rangnekar AS; Fontana RJ
    Aliment Pharmacol Ther; 2012 Jul; 36(2):104-14. PubMed ID: 22612303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.
    De Nicola S; Aghemo A; Rumi MG; Galmozzi E; Valenti L; Soffredini R; De Francesco R; Prati GM; D'Ambrosio R; Cheroni C; Donato MF; Colombo M
    Hepatology; 2012 Feb; 55(2):336-42. PubMed ID: 21932415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.
    Chen Y; Xu HX; Wang LJ; Liu XX; Mahato RI; Zhao YR
    Aliment Pharmacol Ther; 2012 Jul; 36(2):91-103. PubMed ID: 22591106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Host and viral determinants of the outcome of exposure to HCV infection genotype 4: a large longitudinal study.
    Kamal SM; Kassim SK; Ahmed AI; Mahmoud S; Bahnasy KA; Hafez TA; Aziz IA; Fathelbab IF; Mansour HM
    Am J Gastroenterol; 2014 Feb; 109(2):199-211. PubMed ID: 24445571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection.
    Huang CI; Huang CF; Huang JF; Dai CY; Yeh ML; Hsieh MY; Lin ZY; Chen SC; Wang LY; Yu ML; Chuang WL
    J Gastroenterol Hepatol; 2014 May; 29(5):1012-8. PubMed ID: 24325201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.
    Stättermayer AF; Stauber R; Hofer H; Rutter K; Beinhardt S; Scherzer TM; Zinober K; Datz C; Maieron A; Dulic-Lakovic E; Kessler HH; Steindl-Munda P; Strasser M; Krall C; Ferenci P
    Clin Gastroenterol Hepatol; 2011 Apr; 9(4):344-350.e2. PubMed ID: 20728570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study.
    Hu CC; Lin CL; Chang LC; Chien CH; Chen LW; Liu CJ; Chien RN
    BMC Infect Dis; 2015 Mar; 15():156. PubMed ID: 25888020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
    Sakhaee F; Ghazanfari M; Vaziri F; Jamnani FR; Davari M; Gharibzadeh S; Fateh R; Abdolrahimi F; Dizaji SP; Fateh A; Siadat SD
    Infect Genet Evol; 2017 Oct; 54():330-337. PubMed ID: 28739427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis.
    Rangnekar AS; Fontana RJ
    J Viral Hepat; 2013 Jun; 20(6):377-84. PubMed ID: 23647954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-28 and hepatitis C virus genotype-4: treatment-induced clearance and liver fibrosis.
    Derbala M; Rizk N; Shebl F; Alkaabi S; Eldweik N; John A; Sharma M; Yaqoob R; Almohanadi M; Butt M; Alejji K
    World J Gastroenterol; 2012 Dec; 18(47):7003-8. PubMed ID: 23323000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
    Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
    World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High frequencies of a favorable IL-28B rs8099917 polymorphism and the clinical implications in patients with HCV in one multiracial area of Taiwan.
    Cheng CH; Lin CC; Chen HL; Lin IT; Wu CH; Lee YK; Wong MW; Bair MJ
    Kaohsiung J Med Sci; 2017 Oct; 33(10):510-515. PubMed ID: 28962822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients.
    Sarrazin C; Susser S; Doehring A; Lange CM; Müller T; Schlecker C; Herrmann E; Lötsch J; Berg T
    J Hepatol; 2011 Mar; 54(3):415-21. PubMed ID: 21112657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the rapid virologic response a positive predictive factor of sustained virologic response in all pretreatment status genotype 1 hepatitis c patients treated with peginterferon-alpha2b and ribavirin?
    de Segadas-Soares JA; Villela-Nogueira CA; Perez RM; Nabuco LC; Brandão-Mello CE; Coelho HS
    J Clin Gastroenterol; 2009 Apr; 43(4):362-6. PubMed ID: 19077732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive power of Interleukin-28B gene variants for outcome of Hepatitis C Virus genotype 4 in Egyptians: A systematic review and meta-analysis.
    El-Fattah MA
    Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101480. PubMed ID: 32622719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-28b CC genotype predicts early treatment response and CT/TT genotypes predicts non-response in patients infected with HCV genotype 3.
    Gupta AC; Trehanpati N; Sukriti S; Hissar S; Midha V; Sood A; Sarin SK
    J Med Virol; 2014 Apr; 86(4):707-12. PubMed ID: 24415442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.